Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.62 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.62 |
| ▸ | MMP1 | P03956 | 1/20 | 0.58 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.58 |
| ▸ | GSK3B | P49841 | 1/20 | 0.58 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.55 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.55 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.55 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.55 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | CES2 | O00748 | 1/20 | 0.52 |
| ▸ | CES1 | P23141 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5849402 | 0.96 | HDAC1 (0.67) | HDAC1HDAC8MMP1PTPN1GSK3B | |
| SCHEMBL3381534 | 0.95 | HDAC1 (0.69) | HDAC1HDAC8MMP1PTPN1GSK3B | |
| SCHEMBL5849457 | 0.95 | HDAC1 (0.69) | HDAC1HDAC8MMP1PTPN1GSK3B | |
| SCHEMBL5060636 | 0.89 | MMP1 (0.67) | HDAC1HDAC8MMP1PTPN1GSK3B | |
| SCHEMBL26135918 | 0.85 | MMP1 (0.76) | HDAC1HDAC8MMP1PTPN1GSK3B | |
| SCHEMBL7857488 | 0.84 | SMN1; SMN2 (0.66) | HDAC1HDAC8MMP1PTPN1GSK3B | |
| SCHEMBL23049765 | 0.82 | HDAC1 (0.67) | HDAC1HDAC8MMP1PTPN1GSK3B | |
| SCHEMBL2634195 | 0.82 | HTR7 (0.66) | HDAC1HDAC8MMP1PTPN1GSK3B | |
| SCHEMBL5536610 | 0.82 | HDAC1 (0.62) | HDAC1HDAC8MMP1PTPN1GSK3B | |
| SCHEMBL5509133 | 0.82 | HDAC1 (0.62) | HDAC1HDAC8MMP1PTPN1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2023-08-22 | — | — | US | disclosed |
| US-20220002310-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2022-01-06 | — | — | US | disclosed |
| US-11046706-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2021-06-29 | — | — | US | disclosed |
| US-20190300541-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2019-10-03 | — | — | US | disclosed |
| US-10196402-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2019-02-05 | — | — | US | disclosed |
| US-20170362249-A1 | NEW CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2017-12-21 | — | — | US | disclosed |
| US-20170362249-A1 | NEW CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2017-12-21 | — | — | US | disclosed |
| US-9670222-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2017-06-06 | — | — | US | disclosed |
| US-9670222-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2017-06-06 | — | — | US | disclosed |
| US-20140235661-A1 | NEW CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-08-21 | — | — | US | disclosed |
| US-8765949-B2 | CCR2 receptor antagonists and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-01 | — | — | US | disclosed |
| US-8765949-B2 | CCR2 receptor antagonists and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-01 | — | — | US | disclosed |
| US-20130143905-A1 | NOVEL ANTAGONISTS FOR CCR2 AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-06 | — | — | US | disclosed |
| US-20130143905-A1 | NOVEL ANTAGONISTS FOR CCR2 AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-06 | — | — | US | disclosed |
| US-20120004252-A1 | NEW CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-05 | — | — | US | disclosed |
| US-20120004252-A1 | NEW CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-05 | — | — | US | disclosed |
| WO-2011147772-A1 | CCR2 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011073155-A1 | NOVEL ANTAGONISTS FOR CCR2 AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-23 | — | — | WO | disclosed |
| WO-2011073154-A1 | NEW CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190300541-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | CCR2, CCRL2, CCR1 | HDAC1 1612/4885HDAC8 1958/4885MMP1 1494/4885 |
| US-11046706-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | HDAC1 1612/4885HDAC8 1958/4885MMP1 1494/4885 |
| US-20120004252-A1 | NEW CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | CCR2, CCRL2, CCR1 | HDAC1 1627/4885HDAC8 2153/4885MMP1 1464/4885 |
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | HDAC1 1612/4885HDAC8 1958/4885MMP1 1494/4885 |
| US-10196402-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | HDAC1 1612/4885HDAC8 1958/4885MMP1 1494/4885 |
| US-20130143905-A1 | NOVEL ANTAGONISTS FOR CCR2 AND USES THEREOF | CCR2, CCR1, CCRL2 | HDAC1 1090/4885HDAC8 2845/4885MMP1 1122/4885 |
| US-20140235661-A1 | NEW CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | CCR2, CCRL2, CCR1 | HDAC1 1627/4885HDAC8 2153/4885MMP1 1464/4885 |
| US-20170362249-A1 | NEW CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | CCR2, CCRL2, CCR1 | HDAC1 1627/4885HDAC8 2153/4885MMP1 1464/4885 |
| US-20220002310-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | CCR2, CCRL2, CCR1 | HDAC1 1612/4885HDAC8 1958/4885MMP1 1494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.